Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Evofem Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$477.00K. For fiscal 2025 it was -$2.00M. The highest annual figure on record is -$2.00M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.00M | – |
| FY2024 | Dec 31, 2024 | -$3.90M | – |
| FY2023 | Dec 31, 2023 | -$8.97M | – |
| FY2022 | Dec 31, 2022 | -$70.75M | – |
| FY2021 | Dec 31, 2021 | -$149.61M | – |
| FY2020 | Dec 31, 2020 | -$107.08M | – |
| FY2019 | Dec 31, 2019 | -$55.26M | – |
| FY2018 | Dec 31, 2018 | -$56.51M | – |
| FY2017 | Dec 31, 2017 | -$19.25M | – |
| FY2015 | Dec 31, 2015 | -$38.14M | – |
| FY2014 | Dec 31, 2014 | -$9.59M | – |
| FY2013 | Dec 31, 2013 | -$12.93M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.14M | – |
| Q1 FY2026 | Mar 31, 2026 | $2.30M | – |
| Q4 FY2025 | Dec 31, 2025 | $28.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $336.00K | +208.3% |
| Q4 FY2024 | Dec 31, 2024 | -$2.41M | – |
| Q3 FY2024 | Sep 30, 2024 | -$459.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.14M | – |
| Q1 FY2024 | Mar 31, 2024 | $109.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.50M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.37M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.83M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.99M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.32M | – |
| Q3 FY2021 | Sep 30, 2021 | -$37.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$54.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$35.41M | – |
| Q4 FY2020 | Dec 31, 2020 | -$40.50M | – |
| Q3 FY2020 | Sep 30, 2020 | -$36.12M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.49M | – |
| Q1 FY2020 | Mar 31, 2020 | -$14.97M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.59M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.25M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.95M | – |
See a number that looks wrong?